Medical
100 Most Popular
Most Popular Under $25

Corbus Pharmaceuticals

$7.19
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-0.83%) Today
-$0.06 (-0.83%) Today

Why Robinhood?

You can buy or sell CRBP and other stocks, options, ETFs, and crypto commission-free!

About

Corbus Pharmaceuticals Holdings, Inc. Common Stock, also called Corbus Pharmaceuticals, is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Read More The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

Employees
77
Headquarters
Norwood, Massachusetts
Founded
2013
Market Cap
415.04M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.03M
High Today
$7.34
Low Today
$7.13
Open Price
$7.28
Volume
153.30K
52 Week High
$9.11
52 Week Low
$4.50

Collections

Medical
100 Most Popular
Most Popular Under $25
Biotechnology
Pharmaceutical
Health
Therapy
Technology

News

Yahoo FinanceMar 22

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VALE, INGN and CRBP

NEW YORK, NY / ACCESSWIRE / March 22, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies.

1,145
The Motley FoolMar 19

Here's Why Corbus Pharmaceuticals Is on the Move Today

What happened Shares of Corbus Pharmaceuticals (NASDAQ:CRBP), a company developing new drugs that target the endocannabinoid system, started jumping this afternoon after an investor presentation at Oppenheimer (NYSE:OPY). The bank also began analyst coverage with an outperform rating and a price target that implies a 300% gain. As a result, the stock was up 11.9% as of 3:22 p.m. EDT on Tuesday. So what Corbus Pharmaceuticals hasn't received much attention for its endocannabinoid system targeting approach...

6,315
Seeking AlphaMar 19

Corbus Pharmaceuticals Holdings (CRBP) Presents At Oppenheimer 29th Annual Healthcare Conference - Slideshow

The following slide deck was published by Corbus Pharmaceuticals Holdings, Inc. in conjunction with this event. 1 43 Click to enlarge Notes:...

260

Earnings

-$0.30
-$0.25
-$0.19
-$0.14
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.27 per share
Actual
-$0.30 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.